Drug intelligence / Profile preview

RU85053

Development stage: Unknown
Modality: Small Molecules

Overview

RU85053 is an experimental small molecule compound (chemical formula C33H35N3O7) that acts as an inhibitor of the Proto-oncogene tyrosine-protein kinase Src. While primarily studied in the context of non-receptor protein tyrosine kinase signaling, computational drug screening studies in 2020 also identified RU85053 as a potential inhibitor of the SARS-CoV-2 RNA-directed RNA polymerase (RdRp). It has been proposed as a component of a therapeutic cocktail for COVID-19 alongside baloxavir marboxil and natamycin. Currently, the compound remains in the experimental stage with no specific commercial developer or clinical trial data publicly available.

Other names: RU85053RU-85053RU 85053

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)SRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on RU85053.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RU85053.

Explore the full profile